NASDAQ:PHIO

Phio Pharmaceuticals (PHIO) stock rises premarket as new PH-762 skin cancer data keeps traders circling

Phio Pharmaceuticals shares rose 9.8% to $1.23 premarket after reporting no serious adverse events and strong response rates in a Phase 1b skin cancer study of PH-762. Six of seven patients at the highest dose showed a pathological response. The company plans an FDA submission in Q2 2026. The stock gained 24.4% Tuesday.

11 February 2026

NASDAQ:PHIO·Pharmaceuticals·Stock Market

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals’ shares surged over 100% on November 3 after announcing positive Phase 1b results for its PH-762 skin cancer therapy, with one patient achieving full tumor clearance. No serious adverse effects were reported at any dose. The company, with a $12 million pre-rally market cap and no revenue, holds enough cash to fund operations into 2026 but will need more capital for larger trials. Analyst outlooks remain mixed.

3 November 2025

Biotechnology·NASDAQ:PHIO·Stock Market

Union Pacific Stock Seen Undervalued Amid Recent Price Drop
March 20, 2026, 2:10 PM EDT. Union Pacific (ticker: UNP) shares dropped roughly 11% over the past month, now trading near $234. Despite this short-term weakness, the railroad operator maintains positive returns of 1% year-to-date and over 20% across five years. A discounted cash flow (DCF) analysis estimates an intrinsic value around $313 per share, indicating the stock trades about 25% below its cash flow-based valuation, suggesting undervaluation. The price-to-earnings (P/E) metric offers another lens but is secondary to DCF in this review. Investors should weigh recent volatility against Union Pacific's strong long-term fundamentals and sector dynamics before deciding whether current weakness presents a buying opportunity.